Total Payments
$56,176
2024 Payments
$2,294
Companies
10
Transactions
97
Payment Breakdown by Category
Other$34,321 (61.1%)
Consulting$14,650 (26.1%)
Travel$4,408 (7.8%)
Food & Beverage$2,683 (4.8%)
Education$114.02 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $28,235 | 10 | 50.3% |
| Consulting Fee | $14,650 | 5 | 26.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,086 | 5 | 10.8% |
| Travel and Lodging | $4,408 | 16 | 7.8% |
| Food and Beverage | $2,683 | 46 | 4.8% |
| Education | $114.02 | 15 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Horizon Pharma plc | $23,621 | 17 | $0 (2018) |
| Horizon Therapeutics plc | $20,572 | 24 | $0 (2022) |
| BioMarin Pharmaceutical Inc. | $5,958 | 23 | $0 (2020) |
| Ultragenyx Pharmaceutical Inc. | $3,230 | 2 | $0 (2021) |
| Amgen Inc. | $2,075 | 4 | $0 (2024) |
| GENZYME CORPORATION | $564.25 | 9 | $0 (2024) |
| Retrophin, Inc. | $67.96 | 8 | $0 (2019) |
| Shire North American Group Inc | $65.33 | 4 | $0 (2019) |
| ARBOR PHARMACEUTICALS, INC. | $17.94 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,294 | 6 | Amgen Inc. ($2,075) |
| 2023 | $122.57 | 1 | GENZYME CORPORATION ($122.57) |
| 2022 | $7,085 | 12 | Horizon Therapeutics plc ($6,960) |
| 2021 | $3,433 | 4 | Horizon Therapeutics plc ($3,403) |
| 2020 | $13,489 | 17 | Horizon Therapeutics plc ($10,128) |
| 2019 | $264.19 | 13 | Horizon Therapeutics plc ($80.71) |
| 2018 | $12,517 | 23 | Horizon Pharma plc ($12,207) |
| 2017 | $16,970 | 21 | Horizon Pharma plc ($11,413) |
All Payment Transactions
97 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $95.23 | General |
| Category: Genetic Disease | ||||||
| 10/09/2024 | Amgen Inc. | RAVICTI (Biological) | Food and Beverage | In-kind items and services | $36.37 | General |
| Category: Metabolic Disorders/Rare Disease | ||||||
| 10/09/2024 | Amgen Inc. | RAVICTI (Biological) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Metabolic Disorders/Rare Disease | ||||||
| 10/09/2024 | Amgen Inc. | RAVICTI (Biological) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Metabolic Disorders/Rare Disease | ||||||
| 04/05/2024 | Amgen Inc. | RAVICTI (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Metabolic Disorders/Rare Disease | ||||||
| 03/27/2024 | GENZYME CORPORATION | CERDELGA (Drug), CEREZYME | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: Genetic Disease | ||||||
| 06/20/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $122.57 | General |
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $5,600.00 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $474.56 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $350.00 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $148.75 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Travel and Lodging | Cash or cash equivalent | $147.06 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $84.99 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $60.97 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $49.37 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $35.00 | General |
| Category: RAVICTI | ||||||
| 12/09/2022 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | Cash or cash equivalent | $9.08 | General |
| Category: RAVICTI | ||||||
| 05/16/2022 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $124.64 | General |
| Category: Genetic Disease | ||||||
| 04/26/2022 | Travere Therapeutics, Inc. | Cholbam (Drug) | Education | In-kind items and services | $0.83 | General |
| Category: Hepatology | ||||||
| 12/16/2021 | Horizon Therapeutics plc | RAVICTI (Drug) | Food and Beverage | In-kind items and services | $103.22 | General |
| Category: RAVICTI | ||||||
| 09/02/2021 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| Category: RAVICTI | ||||||
| 06/28/2021 | Ultragenyx Pharmaceutical Inc. | Dojolvi (Drug) | Education | In-kind items and services | $30.00 | General |
| Category: Oral nutritional supplements | ||||||
| 03/25/2021 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: RAVICTI | ||||||
| 11/18/2020 | Ultragenyx Pharmaceutical Inc. | DOJOLVI (Drug) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: Oral nutritional supplements | ||||||
| 10/21/2020 | Horizon Therapeutics plc | RAVICTI (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: RAVICTI | ||||||
About Dr. Annette Feigenbaum, M.D
Dr. Annette Feigenbaum, M.D is a Medical Biochemical Genetics healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/06/2011. The National Provider Identifier (NPI) number assigned to this provider is 1902187859.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Annette Feigenbaum, M.D has received a total of $56,176 in payments from pharmaceutical and medical device companies, with $2,294 received in 2024. These payments were reported across 97 transactions from 10 companies. The most common payment nature is "Honoraria" ($28,235).
Ad
Practice Information
- Specialty Medical Biochemical Genetics
- Location San Diego, CA
- Active Since 09/06/2011
- Last Updated 04/25/2024
- Taxonomy Code 207SG0207X
- Entity Type Individual
- NPI Number 1902187859
Products in Payments
- RAVICTI (Drug) $39,162
- BMN 165 (Biological) $5,425
- DOJOLVI (Drug) $3,200
- BUPHENYL (Drug) $2,550
- RAVICTI (Biological) $2,075
- FABRAZYME (Biological) $219.87
- Kuvan (Drug) $160.88
- Vimizim (Biological) $155.41
- Palynziq (Drug) $125.00
- CERDELGA (Drug) $123.92
- (820) Cholbam (Drug) $72.01
- Naglazyme (Biological) $46.41
- VPRIV (Biological) $45.72
- BMN 190 (Biological) $45.50
- GAUCHER-DISEASE (Drug) $40.47
- FABRAZYME (Drug) $40.01
- Dojolvi (Drug) $30.00
- AGRYLIN (Biological) $19.61
- Triptodur (Drug) $17.94
- FABRY-DISEASE (Drug) $17.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.